BBNX

Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

Johnson Fistel Investigation of Beta Bionics prompts caution for BBNX investors

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Johnson Fistel is investigating Beta Bionics for potential securities-law violations tied to Q4 2025 results. Beta Bionics reported at least 5,581 new patient starts and 36% growth, but missed expectations, sending BBNX sharply lower. The outcome could affect BBNX&#039;s valuation and investor sentiment.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel probes Beta Bionics for securities-law violations. Focus on investor losses.</li><li>Q4 2025 topline: new patient starts at least 5,581. Growth at least 36% below estimates.</li><li>Stock fell over 35% after January disclosure. Investor sentiment worsened.</li><li>Investigation seeks potential recovery of losses under securities laws. No cost to investors.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Beta Bionics, Inc. (BBNX)</strong>: Subject of securities-law investigation; Q4 miss cited; potential material impact.</li><li><strong>Johnson Fistel, PLLP (N/A)</strong>: Lead firm behind investigation; potential influence on market perception, not a traded stock.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. Fits as it centers on a securities-law investigation and potential damages to investors; risk to Beta Bionics&#039; valuation from ongoing scrutiny.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>BBNX shares could swing on any updates related to the investigation.</li><li>Q4 miss context may weigh on near-term multiple expansion for BBNX.</li><li>Regulatory headlines likely increase near-term volatility in BBNX.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Beta Bionics Q4 2025 topline: new patient starts at least 5,581.</li><li>YoY growth: at least 36%.</li><li>Prior quarter growth was 68% YoY.</li><li>Jan 9, 2026: BBNX down &gt;35% after disclosures.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term BBNX downside risk exists until the investigation clarity emerges, with volatility likely through the next earnings cycle.</p>
  </section>
</section>


<article>
  <section>
    <h2>Johnson Fistel Investigates Beta Bionics, Inc. for Potential Securities Violations Involving BBNX</h2>
    <p>SAN DIEGO, <strong>June 01, 2026</strong> (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/BBNX"><strong>BBNX</strong></a>) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.</p>
  </section>

  <section>
    <p><strong>What if I purchased Beta Bionics securities?</strong><br/><br/>If you purchased Beta Bionics securities and suffered losses on your investment, join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=rV4rzkP4qKlpjj3NMxkzFByiV0BeTxngDIhSSX3QLVBTVNf9BjMXGeccbdeVmjaXoAYoMpDr4wp3GcaHtSbH18qDLbZ4IPF1aMH4bUIR8Q9zzXWtraTH7-ZurMsa4HFIfVpRE9WhWpjCMUq6uQI9ejGAxsgmHCmXvdvpR4pxT28=" rel="nofollow" target="_blank">Click Here to Join the Investigation</a><strong>.</strong></p>
    <p>Or for more information, contact Jim Baker at <a href="https://www.globenewswire.com/Tracker?data=H8fAE-5VzX5byEKVAIZn4DjRgf4-f1KGrAn6iXB_ePyA3x4C5qW9-zyuM3JHPhxGgQLgAo85w1o5iJfOIig6ZrGq1k54m8p2Ij_R7UodN-Q=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>
    <p>There is no cost or obligation to you.</p>
  </section>

  <section>
    <h3>Background of the Investigation</h3>
    <p>On January 8, 2026, Beta Bionics issued preliminary, unaudited fourth quarter 2025 topline financial results and key operating metrics. The Company reported that new patient starts for the quarter were expected to be at least <strong>5,581</strong>, representing year-over-year growth of at least <strong>36%</strong>. The reported figure was below analyst expectations and reflected a slowdown from the prior quarter, when Beta Bionics reported <strong>68%</strong> year-over-year growth in new patient starts.</p>
    <p>Following the announcement, Beta Bionics' stock price declined more than <strong>35%</strong> on January 9, 2026.</p>
    <p>In light of this disclosure, Johnson Fistel is investigating whether Beta Bionics complied with federal securities laws. If you suffered losses, contact Johnson Fistel for more information.</p>
  </section>

  <section>
    <h3>About Johnson Fistel, PLLP | Securities Fraud & Investor Rights</h3>
    <p>Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder class actions and derivative lawsuits. Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.</p>
    <p>Attorney advertising.</p>
    <p>Past results do not guarantee future outcomes.</p>
    <p>Services may be performed by attorneys in any of our offices.</p>
    <p>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>
  </section>

  <section>
    <h3>Contact</h3>
    <p><strong>Contact</strong><br/>Johnson Fistel, PLLP<br/>501 W. Broadway, Suite 800<br/>San Diego, CA 92101<br/>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br/>(619) 814-4471 &#x7C; <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> &#x7C; <a href="mailto:fjohnson@johnsonfistel.com">fjohnson@johnsonfistel.com</a></p>
  </section>
</article>

Johnson Fistel is investigating Beta Bionics for potential securities-law violations tied to Q4 2025 results. Beta Bionics reported at least 5,581 new patient starts and 36% growth, but missed expectations, sending BBNX sharply lower. The outcome could affect BBNX's valuation and investor sentiment.

Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News